Screener
Myriad Genetics MYGN Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Myriad Genetics’s reported figures.
Based on trailing twelve months.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
FAQ
- What is Myriad Genetics's return on equity?
- Myriad Genetics (MYGN) reported return on equity of -76.7% in Q1 2026.
- How has Myriad Genetics's return on equity changed year-over-year?
- Myriad Genetics's return on equity decreased by 454.3% year-over-year, from -13.8% to -76.7%.
- What is the long-term trend for Myriad Genetics's return on equity?
- Over 5 years (2020 to 2025), Myriad Genetics's return on equity has grown at a 27.4% compound annual growth rate (CAGR), from -20.4% to -68.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Myriad Genetics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude